Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight

prnewswire.com
BIIB Biogen is listed as a key company in the orphan drugs market, which is experiencing strong expansion due to the growing incidence of rare diseases and unmet therapeutic needs. The article does not provide specific details about Biogen's performance or outlook. IONS Ionis Pharmaceuticals is mentioned as a key player in the expanding orphan drugs market. The article highlights the overall market growth driven by rare diseases and government support, but offers no specific sentiment for Ionis. ALNY Alnylam Pharmaceuticals is listed as a key company in the orphan drugs market, which is projected to grow significantly. The article does not offer specific details or sentiment regarding Alnylam's individual performance or prospects within this market. AZN AstraZeneca is identified as a key company in the orphan drugs market, which is experiencing robust growth. The article provides no specific information or sentiment regarding AstraZeneca's individual contribution or future outlook in this sector. GILD Gilead Sciences is named as a significant company within the orphan drugs market, which is poised for substantial growth. The article does not offer specific sentiment or analysis pertaining to Gilead's individual performance or strategic position. JNJ Johnson & Johnson is listed as a key player in the orphan drugs market, which is experiencing strong expansion. The article does not provide specific details or sentiment regarding Johnson & Johnson's individual performance or outlook in this sector. BMRN BioMarin Pharmaceutical is mentioned as a key company in the orphan drugs market, which is expected to grow significantly. The article does not provide specific sentiment or analysis for BioMarin's individual performance or prospects. VRTX Vertex Pharmaceuticals is listed as a key company in the expanding orphan drugs market. The article highlights the overall market growth drivers but offers no specific sentiment or detailed analysis for Vertex's individual performance. ASTL Astellas Pharma is named as a key company in the orphan drugs market, which is expected to grow significantly. The article does not provide specific sentiment or analysis for Astellas Pharma's individual performance or outlook. PFE Pfizer is listed as a key company in the orphan drugs market, which is experiencing strong growth. The article does not provide specific sentiment or analysis regarding Pfizer's individual performance or prospects in this sector. NVO Novo Nordisk is mentioned as a key company in the orphan drugs market, which is projected to grow substantially. The article does not offer specific sentiment or analysis for Novo Nordisk's individual performance or outlook. REGN Regeneron Pharmaceuticals is listed as a key company in the orphan drugs market, which is experiencing strong expansion. The article does not provide specific sentiment or analysis regarding Regeneron's individual performance or prospects.

Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight The orphan drugs market is seeing strong expansion, propelled by the growing worldwide incidence of genetic conditions and other rare diseases, as well as the substantial unmet need for effective therapies. With many rare disorders still lacking adequate treatment options, the market holds considerable potential. Supportive government initiatives and regulatory benefits, including extended market exclusivity and faster approval processes, are also accelerating orphan drug development.

LAS VEGAS, March 4, 2026 /PRNewswire/ -- DelveInsight's Orphan Drugs Market Insights report provides the current and forecast market analysis, individual leading orphan drugs companies' market shares, challenges, orphan drugs market drivers, barriers, trends, and key orphan drugs companies in the market.

Orphan Drugs Market Summary

To read more about the latest highlights related to the orphan drugs market, get a snapshot of the key highlights @ https://www.delveinsight.com/sample-request/orphan-drugs-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

Key Factors Contributing to the Rise in Growth of the Orphan Drugs Market

Regional Orphan Drugs Market Insights

North America

North America remains the largest market for orphan drugs, driven by:

Europe

Europe represents the second-largest regional market, with growth supported by:

Asia-Pacific

Asia-Pacific is the fastest-growing regional market, propelled by:

Latin America

Latin America is emerging as a promising market, with:

Middle East & Africa

The Middle East & Africa region shows growing yet nascent opportunities:

Get a sneak peek at the orphan drugs market dynamics @ Orphan Drugs Market Trends

Recent Developmental Activities in the Orphan Drugs Market

What are Orphan Drugs?

Orphan drugs are medicines developed to diagnose, prevent, or treat rare diseases, conditions that affect only a small percentage of the population. Because the potential market for these drugs is very limited, pharmaceutical companies often lack financial incentives to invest in their research and development. To address this gap, many governments offer special benefits such as tax credits, grants, fee waivers, and market exclusivity to encourage the production of these treatments. As a result, orphan drugs play a crucial role in providing life-changing therapies for patients who might otherwise have no available medical options.

Orphan Drugs Market Report Metrics

Details

Coverage

Global

Study Period

2022–2032

Orphan Drugs Market CAGR

~7%

Orphan Drugs Market Size by 2032

USD 357 Billion

Key Orphan Drugs Companies

Sanofi, Biogen, Ionis Pharmaceuticals, Inc., Novartis AG, Alnylam Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., Mitsubishi Tanabe Pharma Corporation, BioMarin Pharmaceutical Inc., Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc., Kyowa Kirin Co., Ltd., Catalyst Pharmaceuticals, Inc., Chugai Pharmaceutical Co., Ltd., Sarepta Therapeutics, Inc., Astellas Pharma Inc., Pfizer Inc., Novo Nordisk A/S, and others

Orphan Drugs Market Assessment

Which MedTech key players in the orphan drugs market are set to emerge as the trendsetter explore @ Orphan Drugs Market Analysis

Table of Contents

1

Orphan Drugs Market Report Introduction

2

Orphan Drugs Market Executive Summary

3

Competitive Landscape

4

Regulatory Analysis

5

Orphan Drugs Market Key Factors Analysis

6

Orphan Drugs Market Porter's Five Forces Analysis

7

Orphan Drugs Market Layout

8

Orphan Drugs Market Company and Product Profiles

9

KOL Views

10

Project Approach

11

About DelveInsight

12

Disclaimer & Contact Us

Interested in knowing the orphan drugs market share by 2032? Click to get a snapshot of the Orphan Drugs Market Size

Related Reports

Hemophilia Market

Hemophilia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hemophilia companies, including Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk, and others.

Von Willebrand Disease Market

Von Willebrand Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key VWD companies, including CSL Behring, LFB Biomedicaments SA, Octapharma AG, Grifols SA, and others.

Spinal Muscular Atrophy Market

Spinal Muscular Atrophy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SMA companies, including Scholar Rock, Biohaven/ Bristol-Myers Squibb, F. Hoffmann-La Roche, NMD Pharma, and others.

Rare Disease Consulting Services: In the rare disease space, one of our fortes, we deliver intelligence that helps clients overcome the unique challenges of niche markets. Our analysts monitor global R&D progress, competitive developments, and shifting regulatory landscapes to provide tailored insights that guide product positioning and investment strategies. From in-depth conference evaluations to detailed competitor analyses, we help clients de-risk decision-making, strengthen portfolios, and efficiently advance therapies from development to market.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Contact Us

Shruti Thakur

[email protected]

+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP